At a glance
ClinicalIndex Comparison RecordPhase 2Withdrawn· 0 enrolled
Drug / intervention
Pembrolizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, Open-label Phase II Study of Lenvatinib Plus Pembrolizumab (LEAP) in Renal Cell Carcinoma Patients With Brain Metastasis Previously Treated With Immune Checkpoint Blockade
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab and Lenvatinib for Renal Cell Carcinoma and Brain Metastasis. Withdrawn before enrollment.
Signals
Trial was withdrawn before enrollment
Detailed Summary
This is a multi-center, open-label phase II study evaluating the efficacy and safety of pembrolizumab in combination with lenvatinib in patients with renal cell carcinoma (RCC) and brain metastasis who were previously treated with immune checkpoint blockade.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Cell Carcinoma, Brain Metastasis
Countries--
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2WithdrawnFinished
2026
Enrollment StartJun 2025
First PostedJun 2025
Primary CompletionAug 2025
TodayJul 2026
First PostedJun 10, 2025
Enrollment StartJun 4, 2025
Primary CompletionAug 7, 2025
TodayJul 1, 2026
Enrollment to primary: 2 monthsPosted 1.1 years ago
Interventions
Pembrolizumabdrug
Given by IV
Lenvatinibdrug
Given by mouth